Rationale and design of the HOVON 170 DLBCL-ANTICIPATE trial: preventing anthracycline-induced cardiac dysfunction with dexrazoxane by Marijke Linschoten, Jesse Geels, Erik van Werkhoven, Heleen Visser-Wisselaar, Martine E. D. Chamuleau, Arco J. Teske, Lourens Robbers, Simone Oerlemans, Heleen Crommelin, Marleen Breems-de Ridder, Astrid Schut, Folkert W. Asselbergs, Anna van Rhenen, on behalf of the HOVON 170 DLBCL – ANTICIPATE consortium

“…This trial aims to establish the efficacy and safety of dexrazoxane for the primary prevention of AICD in patients diagnosed with Diffuse Large B-Cell Lymphoma (DLBCL) treated with six cycles R-CHOP21 chemo-immunotherapy. Methods This is a multicenter, parallel-group, open-label, phase III trial, randomizing 324 patients between either no cardioprotective treatment or dexrazoxane from the first R-CHOP cycle. …”
Get full text

Changes in and Potential Mechanisms of Circulating IgA+CD27-Class-Switched Memory B Cells in Patients With Allergic Rhinitis by Zheng H, Xu S, Yang R, Jiao WE, Qiao YL, Liu JY, Fan HM, Zhou YT, Ni HF, Chen J, Deng YQ, Chen SM

“…Han Zheng,1,* Shan Xu,1,* Rui Yang,1,* Wo-Er Jiao,1 Yue-Long Qiao,1,2 Jia-Yu Liu,1 Hui-Ming Fan,1 Yan-Ting Zhou,1 Hai-Feng Ni,3 Jin Chen,1 Yu-Qin Deng,1 Shi-Ming Chen1 1Department of Otolaryngology-Head and Neck Surgery, Renmin Hospital of Wuhan University, Wuhan, Hubei, People’s Republic of China; 2Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, Davos, Switzerland; 3Department of Otolaryngology-Head and Neck Surgery, Zhejiang Hospital, Hangzhou, Zhejiang, People’s Republic of China*These authors contributed equally to this workCorrespondence: Yu-Qin Deng; Shi-Ming Chen, Department of Otolaryngology-Head and Neck Surgery, Renmin Hospital of Wuhan University, Wuhan, Hubei, People’s Republic of China, Email bamboo0723@126.com; shimingchen0468@163.comBackground: The role of memory B cells and their subgroups in allergic rhinitis (AR) and allergen immunotherapy (AIT) remains unclear. This study aimed to investigate the characteristics of memory B cells in the circulation of patients with AR and those undergoing AIT, as well as their clinical significance.Methods: This study involved a cohort comprising 32 healthy control subjects, 39 individuals diagnosed with AR, and 31 AR patients who had received AIT for over one year. …”
Get full text

Participant experiences in HIV cure-directed trial with an extended analytical treatment interruption in Philadelphia, United States by Andrea Bilger, Eion Plenn, Frances K. Barg, Katharine A. Rendle, William B. Carter, Andrea Lamour-Harrington, Nora Jones, Beth Peterson, John A. Sauceda, Pablo Tebas, Karam Mounzer, David Metzger, Luis J. Montaner, Karine Dubé

“…Methods From April to November 2022, we conducted post-ATI in-depth interviews with BEAT2 clinical trial (NCT03588715) participants who stopped ART while receiving an immunotherapy regimen. We used conventional content analysis to code the data. …”
Get full text

Identification of SETD4 as an Onco‐Immunological Biomarker Encompassing the Tumor Microenvironment, Prognoses, and Therapeutic Responses in Various Human Cancers by Yuyun Zhong, Ruiqi Wang, Zijie Huang, Zhaoting Hu, Bin Peng, Bin Chen, Liyue Sun

“…Furthermore, we investigated its association with cancer‐related pathways, the immune microenvironment, immunotherapy markers, and drug resistance signatures of chemotherapy. …”
Get full text

YTHDF2 in peritumoral hepatocytes mediates chemotherapy-induced antitumor immune responses through CX3CL1-mediated CD8+ T cell recruitment by Zhenyun Yang, Xin Wang, Yizhen Fu, Weijie Wu, Zili Hu, Qingyang Lin, Wei Peng, Yangxun Pan, Juncheng Wang, Jinbin Chen, Dandan Hu, Zhongguo Zhou, Li Xu, Yaojun Zhang, Jiajie Hou, Minshan Chen

“…Additionally, YTHDF2 mediated the response to immunotherapy. Mechanistically, OXA upregulated YTHDF2 expression by activating the cGAS-STING signaling pathway and consequently enhanced the therapeutic outcomes of immunotherapeutic interventions. …”
Get full text

Ferroptosis: A novel cell death modality as a synergistic therapeutic strategy with photodynamic therapy by Yuqing Wang, Yiting Xu, Yong Qu, Yifang Jin, Juanmei Cao, Jinshan Zhan, Zhuoxia Li, Chuxing Chai, Changzheng Huang, Min Li

“…Hence, the development of precisely targeted tumor therapies and exploration of immunotherapy represent additional strategies for tumor treatment. …”
Get full text

Plasma S100A8/A9 level predicts response to immune checkpoint inhibitors in patients with advanced non-small cell lung cancer by Tadahiro Kuribayashi, Rie Kinoshita, Kiichiro Ninomiya, Go Makimoto, Toshio Kubo, Kammei Rai, Eiki Ichihara, Katsuyuki Hotta, Masahiro Tabata, Yoshinobu Maeda, Katsuyuki Kiura, Shinichi Toyooka, Masakiyo Sakaguchi, Kadoaki Ohashi

“…We investigated the association of the plasma level of S100A8/A9 with the efficacy of immunotherapy. We evaluated patients with unresectable stage III/IV or recurrent non-small cell lung cancer (NSCLC) who were treated with ICIs at Okayama University Hospital. …”
Get full text

MicroRNA-3145 as a potential therapeutic target for hepatitis B virus: inhibition of viral replication via downregulation of HBS and HBX by Amrizal Muchtar, Amrizal Muchtar, Daichi Onomura, Daichi Onomura, Dan Ding, Dan Ding, Hironori Nishitsuji, Kunitada Shimotohno, Shunpei Okada, Keiji Ueda, Koichi Watashi, Takaji Wakita, Kei Iida, Kei Iida, Hironori Yoshiyama, Hisashi Iizasa

Get full text

Identification of a distinctive immunogenomic gene signature in stage-matched colorectal cancer by Pankaj Ahluwalia, Ashis K. Mondal, Ashutosh Vashisht, Harmanpreet Singh, Ahmet Alptekin, Kalyani Ballur, Nivin Omar, Meenakshi Ahluwalia, Kimya Jones, Amanda Barrett, Vamsi Kota, Ravindra Kolhe

“…Despite advances in diagnosis and treatment, including surgery, chemotherapy, and immunotherapy, accurate clinical markers are still lacking. …”
Get full text

Hepatocellular carcinoma: signaling pathways and therapeutic advances by Jiaojiao Zheng, Siying Wang, Lei Xia, Zhen Sun, Kui Ming Chan, René Bernards, Wenxin Qin, Jinhong Chen, Qiang Xia, Haojie Jin

“…New trials are investigating combination therapies involving ICIs and TKIs or anti-VEGF (endothelial growth factor) therapies, as well as combinations of two immunotherapy regimens. The outcomes of these trials are expected to revolutionize HCC management across all stages. …”
Get full text

Intravenous versus subcutaneous tocilizumab in Takayasu arteritis: multicentre retrospective study by Patrice Cacoub, Arsène Mekinian, David Saadoun, Pavel I Novikov, Savino Sciascia, Corrado Campochiaro, Olivier Fain, Ilya Smitienko, Nicolas Schleinitz, Patrick Jégo, Francesco Muratore, Carlo Salvarani, Elena Galli, Sabine Berthier, Marc Lambert, François Maurier, Isabelle Kone-Paut, Sergey Moiseev, Masataka Kuwana, Alexandre Belot, Martin Michaud, Francis Gaches, Achille Aouba, Xavier Puechal, Karim Sacre, Tiphaine Goulenok, Alessandro Tomelleri, Thomas Sené, Elena Marina Baldissera, Luigi Boiardi, Abid Awisat, Ygal Benhamou, Vahan Mukuchyan, Mathieu Vautier, Azeddine Dellal, Lucie Biard, Julie Seguier, José Hernández-Rodríguez, Olivier Espitia, Sebastien Humbert, Guillaume Denis, Nolan Hassold, Dagna Lorenzo, Helene Munoz Pons, Jean Baptiste Gaultier, Le Mouel Edwige, Antoinette Perlat, Bertrand Lioger, Jonathan Broner, Virginie Dufrost, Faten Frikha, Alexandra Audemard-Verger, Pascal Woaye-Hune, Pierre Zeminsky, Moya Alvarado, Matheus Vieira, Alberto Lo Gullo

Get full text

circ-1584 selectively promotes the antitumor activity of the oncolytic virus M1 on pancreatic cancer by Taofang Hao, Yuanyuan Li, Qianyao Ren, Ying Zeng, Leyi Gao, Wenbo Zhu, Jiankai Liang, Yuan Lin, Jun Hu, Guangmei Yan, Shuxin Sun, Jing Cai

“…Pancreatic cancer is among the most challenging tumors to treat, and due to its immune tolerance characteristics, existing immunotherapy methods are not effective in alleviating the disease. …”
Get full text

The impact of CD3ζ ITAM multiplicity and sequence on CAR T-cell survival and function by Shubhabrata Majumdar, Hilda Echelibe, Maria Bettini, Matthew L. Bettini

“…IntroductionChimeric antigen receptor (CAR) expressing T-cells have shown great promise for the future of cancer immunotherapy with the recent clinical successes achieved in treating different hematologic cancers. …”
Get full text

LncRNAs in serum-derived extracellular vesicles are potential biomarker and correlated with immune infiltration in gastric cancer by Juan Ding, Yunyan Teng, Rongshu Cui, Jin Liu, Ke Xiao, Zhaogang Dong, Yi Zhang, Xiaofei Xu

“…It provides a foundation for the development of serum EV-targeted novel biomarkers and immunotherapy targets of GC.…”
Get full text

Immune infiltration landscape and potential drug-targeted implications for hepatocellular carcinoma with ‘progression/hyper-progression’ recurrence by Jing-Xuan Xu, Yue-Xiang Su, Yuan-Yuan Chen, Yi-Yue Huang, Zu-Shun Chen, Yu-Chong Peng, Lu-Nan Qi

“…Virtual docking was used to identify potential therapeutic targets, and the results were verified using single-nuclei RNA sequencing and histological analysis.Results ITM was closely related to type III–IV recurrence and exhibited immunotherapy potential. The potential efficacy of inhibiting CCNA2, VEGFA, CXCL8, PLK2, TIMP1, ITGB2, ALDOA, ANXA5 and CSK in ITM reversal was determined. …”
Get full text

CC-96673 (BMS-986358), an affinity-tuned anti-CD47 and CD20 bispecific antibody with fully functional fc, selectively targets and depletes non-Hodgkin’s lymphoma by Dan Zhu, Haralambos Hadjivassiliou, Catherine Jennings, David Mikolon, Massimo Ammirante, Sharmistha Acharya, Jon Lloyd, Mahan Abbasian, Rama Krishna Narla, Joseph R. Piccotti, Katie Stamp, Ho Cho, Kandasamy Hariharan

“…The CD47-SIRPα axis has become an important target for cancer immunotherapy. To date, the advancement of CD47-targeted modalities is hindered by the ubiquitous expression of the target, often leading to rapid drug elimination and hematologic toxicity including anemia. …”
Get full text

Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes in Advanced Melanoma Patients by Mélanie Saint-Jean, Anne-Chantal Knol, Christelle Volteau, Gaëlle Quéreux, Lucie Peuvrel, Anabelle Brocard, Marie-Christine Pandolfino, Soraya Saiagh, Jean-Michel Nguyen, Christophe Bedane, Nicole Basset-Seguin, Amir Khammari, Brigitte Dréno

“…Immunotherapy for melanoma includes adoptive cell therapy with autologous tumor-infiltrating lymphocytes (TILs). …”
Get full text

A prognostic signature of Glutathione metabolism-associated long non-coding RNAs for lung adenocarcinoma with immune microenvironment insights by Junxi Hu, Junxi Hu, Shuyu Tian, Shuyu Tian, Qingwen Liu, Qingwen Liu, Jiaqi Hou, Jiaqi Hou, Jun wu, Jun wu, Xiaolin Wang, Xiaolin Wang, Yusheng Shu, Yusheng Shu

“…High-risk patients showed increased tumor mutation burden (TMB) and stemness, emphasizing the potential of personalized immunotherapy to improve survival outcomes.…”
Get full text

The landscape of immunogenic cell death-related genes predicts the overall survival and immune infiltration status of non-small-cell lung carcinoma by Jian Zhang, Huiying Li, Xi Zhang, Yue Yang, Yue Sun

“…Immunogenic cell death (ICD), a form of regulated cell death capable of activating adaptive immune responses and generating long-term immune memory, holds promise for enhancing anti-tumor immunity and offering promising prospects for immunotherapy strategies in NSCLC. Methods: Clinical information and expressive profiles of NSCLC genes were retrieved from the GEO and TCGA databases. …”
Get full text

Spatial tumor immune heterogeneity facilitates subtype co-existence and therapy response in pancreatic cancer by Lukas Klein, Mengyu Tu, Niklas Krebs, Laura Urbach, Daniela Grimm, Muhammad Umair Latif, Frederike Penz, Anna Blandau, Xueyan Wu, Rebecca Diya Samuel, Stefan Küffer, Florian Wegwitz, Nathan Chan, Kazeera Aliar, Foram Vyas, Uday Kishore, Elisabeth Hessmann, Andreas Trumpp, Elisa Espinet, Argyris Papantonis, Rama Khokha, Volker Ellenrieder, Barbara T. Grünwald, Shiv K. Singh

“…Consequently, combined preclinical anti-TNF-α immunotherapy and chemotherapy reduces macrophages and promotes CD3+/CD8+ T cell infiltration in basal-like PDAC, improving survival. …”
Get full text